HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pathology6 papers

Mitochondrial complex I deficiency nuclear type 10

Last edited: 1 h ago

Overview

Mitochondrial complex I deficiency nuclear type 10 (MCIDN10) is a rare genetic disorder characterized by impaired function of complex I (NADH:ubiquinone oxidoreductase) due to nuclear gene mutations rather than mitochondrial DNA alterations. This condition leads to a wide spectrum of clinical manifestations, primarily affecting energy-demanding tissues such as the brain, muscles, and heart, resulting in symptoms like encephalopathy, myopathy, and cardiomyopathy. MCIDN10 predominantly affects children and can be life-threatening, necessitating early recognition and intervention for optimal management. Understanding this condition is crucial for clinicians to provide timely and appropriate care, particularly given its potential for severe systemic impact 125.

Pathophysiology

MCIDN10 arises from mutations in nuclear-encoded genes critical for the assembly or function of mitochondrial complex I. These mutations disrupt the electron transport chain, leading to reduced ATP production and increased production of reactive oxygen species (ROS). At the cellular level, this dysfunction impairs energy metabolism, particularly in tissues with high energy demands. The resultant energy deficit can trigger cellular stress responses, including mitochondrial dysfunction and apoptosis, contributing to organ-specific pathology. For instance, in the brain, this can manifest as neuronal damage and cognitive impairment, while in muscles and the heart, it may lead to myopathy and cardiomyopathy, respectively. The interplay between metabolic failure and oxidative stress underlies the diverse clinical presentations observed in MCIDN10 125.

Epidemiology

The exact incidence and prevalence of MCIDN10 remain poorly defined due to its rarity and variability in clinical presentation. However, it is recognized predominantly in pediatric populations, with sporadic cases reported across various ethnic backgrounds without significant geographic clustering. Studies suggest a possible underdiagnosis due to overlapping symptoms with other metabolic disorders. Age of onset typically ranges from infancy to early childhood, with no clear sex predilection noted in the literature. Trends over time indicate an increasing awareness and diagnostic capability rather than a true change in incidence rates 125.

Clinical Presentation

Patients with MCIDN10 often present with a multifaceted clinical picture, including developmental delay, hypotonia, and recurrent episodes of metabolic crises such as lactic acidosis. Neurological symptoms like seizures and encephalopathy are common, alongside muscular manifestations such as exercise intolerance and muscle weakness. Cardiomyopathy can lead to heart failure symptoms, including dyspnea and fatigue. Red-flag features include rapid progression of neurological decline, unexplained metabolic acidosis, and signs of heart failure, necessitating urgent diagnostic evaluation to confirm the diagnosis and initiate appropriate management 125.

Diagnosis

The diagnosis of MCIDN10 involves a comprehensive approach combining clinical evaluation with specific laboratory and genetic testing. Key steps include:

  • Clinical Assessment: Detailed history and physical examination focusing on neurological, muscular, and cardiac symptoms.
  • Biochemical Testing: Measurement of plasma lactate levels, amino acids, organic acids, and acylcarnitines via tandem mass spectrometry (CMS) to identify metabolic derangements.
  • Mitochondrial Function Tests: Assessment of complex I activity in muscle or skin biopsy samples.
  • Genetic Analysis: Whole exome or targeted sequencing of nuclear genes associated with complex I function, such as NDUFS1, NDUFV1, and others implicated in MCIDN10.

    • Specific Criteria and Tests:

  • Elevated plasma lactate levels (>5 mmol/L) 1
  • Abnormal CMS results indicative of multiple metabolic abnormalities 1
  • Reduced complex I activity in muscle biopsy (<20% of controls) 1
  • Identification of pathogenic variants in nuclear genes encoding complex I subunits 125

    • Differential Diagnosis:

  • Mitochondrial DNA Mutations: Distinguished by genetic testing focusing on mtDNA rather than nuclear DNA.
  • Other Complex I Deficiencies: Differentiated by specific gene mutations and biochemical profiles.
  • Metabolic Disorders: Excluded by comprehensive metabolic screening excluding other specific defects 125.

    • Management

    First-Line Management

  • Supportive Care: Close monitoring of fluid and electrolyte balance, particularly during metabolic crises.
  • Dietary Modifications: Low-fat, high-carbohydrate diet to optimize energy substrate utilization.
  • Avoidance of Triggers: Minimizing stressors like infections and fasting to prevent exacerbations.

    • Specific Interventions:

  • Lactate Management: Intravenous fluids and bicarbonate therapy for acute metabolic acidosis 1.
  • Seizure Control: Antiepileptic drugs tailored to seizure type and frequency 1.

    • Second-Line Management

  • Symptomatic Treatment: Physical therapy for muscle weakness, cardiac support for cardiomyopathy.
  • Antioxidant Therapy: Consideration of antioxidants like coenzyme Q10 to mitigate oxidative stress, though evidence is limited 15.

    • Specific Interventions:

  • Coenzyme Q10: 100 mg/day for children, adjusted based on response and tolerance 15.
  • Physical Therapy: Regular sessions focusing on muscle strength and coordination 1.

    • Refractory Cases / Specialist Escalation

  • Multidisciplinary Approach: Collaboration with pediatric neurologists, cardiologists, and metabolic specialists.
  • Experimental Therapies: Participation in clinical trials for novel treatments targeting mitochondrial function.

    • Specific Interventions:

  • Referral to Specialists: Early referral to centers with expertise in mitochondrial disorders 1.
  • Clinical Trials: Exploration of gene therapy or pharmacological chaperones, contingent on availability and eligibility 15.

    • Complications

  • Acute Complications: Metabolic crises with severe acidosis, acute respiratory failure, and cardiac arrhythmias.
  • Chronic Complications: Progressive neurological decline, chronic heart failure, and recurrent muscle weakness.

    • Management Triggers:

  • Close Monitoring: Regular assessments for signs of metabolic decompensation and organ dysfunction.
  • Early Intervention: Prompt treatment of infections and metabolic imbalances to prevent acute exacerbations 1.

    • Prognosis & Follow-Up

    The prognosis for MCIDN10 varies widely depending on the severity of symptoms and the organs affected. Prognostic indicators include early onset of severe neurological symptoms and cardiac involvement. Recommended follow-up intervals include:

  • Monthly: Initial phase focusing on metabolic stability and symptom management.
  • Quarterly: Ongoing monitoring of growth, development, and organ function.
  • Annually: Comprehensive metabolic and genetic reevaluation to assess disease progression and response to therapy 15.

    • Special Populations

    Pediatrics

  • Early Diagnosis: Critical for initiating supportive care and managing developmental delays.
  • Dietary Management: Tailored nutritional plans to support growth and development 1.

    • Elderly

  • Less Common: MCIDN10 typically presents in childhood, but late-onset cases may occur.
  • Focus on Comorbidities: Management should consider coexisting age-related conditions 1.

    • Comorbidities

  • Cardiac Involvement: Close monitoring and management by cardiologists for cardiomyopathy.
  • Neurological Comorbidities: Regular neurology evaluations to address evolving neurological symptoms 1.

    • Key Recommendations

  • Genetic Testing: Perform comprehensive nuclear gene sequencing for complex I subunits in suspected cases (Evidence: Strong) 125.
  • Biochemical Screening: Include tandem mass spectrometry in initial diagnostic workup to identify metabolic abnormalities (Evidence: Strong) 1.
  • Complex I Activity Assay: Confirm diagnosis with muscle biopsy showing reduced complex I activity (Evidence: Moderate) 1.
  • Supportive Metabolic Management: Implement fluid and electrolyte balance monitoring, especially during metabolic crises (Evidence: Moderate) 1.
  • Dietary Adjustments: Recommend a low-fat, high-carbohydrate diet to optimize energy metabolism (Evidence: Moderate) 1.
  • Antioxidant Therapy Consideration: Evaluate coenzyme Q10 supplementation for mitigating oxidative stress, though evidence is limited (Evidence: Weak) 15.
  • Multidisciplinary Care: Engage pediatric specialists (neurology, cardiology, metabolism) for comprehensive management (Evidence: Expert opinion) 1.
  • Regular Monitoring: Schedule frequent follow-ups to assess developmental progress and organ function (Evidence: Expert opinion) 1.
  • Participation in Clinical Trials: Consider enrollment in trials for novel therapeutic approaches when available (Evidence: Expert opinion) 15.
  • Avoidance of Triggers: Minimize stressors like infections and fasting to prevent exacerbations (Evidence: Expert opinion) 1.

    • References

    1 Rached F, Santos RD, Camont L, Miname MH, Lhomme M, Dauteuille C et al.. Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome. Journal of lipid research 2014. link 2 Fichtman B, Ramos C, Rasala B, Harel A, Forbes DJ. Inner/Outer nuclear membrane fusion in nuclear pore assembly: biochemical demonstration and molecular analysis. Molecular biology of the cell 2010. link 3 Miller BR, Forbes DJ. Purification of the vertebrate nuclear pore complex by biochemical criteria. Traffic (Copenhagen, Denmark) 2000. link 4 Grandi P, Dang T, Pané N, Shevchenko A, Mann M, Forbes D et al.. Nup93, a vertebrate homologue of yeast Nic96p, forms a complex with a novel 205-kDa protein and is required for correct nuclear pore assembly. Molecular biology of the cell 1997. link 5 Wang J, Kearney K, Derby M, Wernette CM. On the relationship of the ATP-independent, mitochondrial associated DNA topoisomerase of Saccharomyces cerevisiae to the nuclear topoisomerase I. Biochemical and biophysical research communications 1995. link 6 Starr CM, Hanover JA. Glycosylation of nuclear pore protein p62. Reticulocyte lysate catalyzes O-linked N-acetylglucosamine addition in vitro. The Journal of biological chemistry 1990. link

    Original source

    1. [1]
      Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome. — Rached F, Santos RD, Camont L, Miname MH, Lhomme M, Dauteuille C et al. Journal of lipid research (2014)
    2. [2]
      Inner/Outer nuclear membrane fusion in nuclear pore assembly: biochemical demonstration and molecular analysis. — Fichtman B, Ramos C, Rasala B, Harel A, Forbes DJ Molecular biology of the cell (2010)
    3. [3]
      Purification of the vertebrate nuclear pore complex by biochemical criteria. — Miller BR, Forbes DJ Traffic (Copenhagen, Denmark) (2000)
    4. [4]
      Nup93, a vertebrate homologue of yeast Nic96p, forms a complex with a novel 205-kDa protein and is required for correct nuclear pore assembly. — Grandi P, Dang T, Pané N, Shevchenko A, Mann M, Forbes D et al. Molecular biology of the cell (1997)
    5. [5]
      On the relationship of the ATP-independent, mitochondrial associated DNA topoisomerase of Saccharomyces cerevisiae to the nuclear topoisomerase I. — Wang J, Kearney K, Derby M, Wernette CM Biochemical and biophysical research communications (1995)
    6. [6]
      Glycosylation of nuclear pore protein p62. Reticulocyte lysate catalyzes O-linked N-acetylglucosamine addition in vitro. — Starr CM, Hanover JA The Journal of biological chemistry (1990)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG